share_log

RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $61

RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $61

RBC Capital维持对ideaya生物科学的跑赢大盘评级,将目标价上调至61美元。
Benzinga ·  07/11 10:53

RBC Capital analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $53 to $61.

RBC Capital分析师Gregory Renza维持对ideaya生物科学(纳斯达克:IDYA)的Outperform评级,将目标价从53美元提高至61美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发